Showing results (1-10 of 9) with videos related to
Sort By:
Pageof 1
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|April 7, 2019
Accuracy of budget impact estimations and impact on patient access: a hepatitis C case studyJoost W Geenen, Cornelis Boersma, Olaf H Klungel, et al.Journal of Market Access & Health Policy|December 17, 2019
Affordability of oncology drugs: accuracy of budget impact estimationsJoost W Geenen, Mark Jut, Cornelis Boersma, et al.Pharmacoeconomics|December 14, 2020
The Application and Implications of Novel Deterministic Sensitivity Analysis MethodsRick A Vreman, Joost W Geenen, Saskia Knies, et al.Applied Health Economics and Health Policy|July 19, 2019
Phase I/II Clinical Trial-Based Early Economic Evaluation of Acalabrutinib for Relapsed Chronic Lymphocytic LeukaemiaRick A Vreman, Joost W Geenen, Anke M Hövels, et al.Cost Effectiveness and Resource Allocation : C/E|December 9, 2020
Increasing the information provided by probabilistic sensitivity analysis: The relative density plotJoost W Geenen, Rick A Vreman, Cornelis Boersma, et al.The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|April 6, 2020
A novel method for predicting the budget impact of innovative medicines: validation study for oncolyticsJoost W Geenen, Svetlana V Belitser, Rick A Vreman, et al.Journal of Comparative Effectiveness Research|November 2, 2017
Cost of illness of metastatic prostate cancer: a perspective of costs for new treatment options in The NetherlandsRob Ter Heine, Geert Wj Frederix, Joost W Geenen, et al.Pharmacogenomics|July 27, 2017
Early health technology assessments in pharmacogenomics: a case example in cardiovascular drugsJoost W Geenen, Ekaterina V Baranova, Folkert W Asselbergs, et al.European Journal of Human Genetics : EJHG|July 1, 2018
Whole-exome sequencing in intellectual disability; cost before and after a diagnosisTerry Vrijenhoek, Eline M Middelburg, Glen R Monroe, et al.Pageof 1